Clinical TrialsGenmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Genmab’s Epcoritamab Plus R2 Maintains Strong Benefit Across Risk Gro... Read Post »
Clinical TrialsCullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Cullinan Reports Promising Phase 1 Results for CLN-978 and Velinotamig Read Post »
Clinical TrialsFDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results FDA Backs Phase 3 Plan as Enliven Posts Strong Phase 1 CML Results Read Post »
Clinical TrialsZiftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Ziftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET... Read Post »
Clinical TrialsSix-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Six-Year SEQUOIA Data Highlight Durable BRUKINSA Benefit in CLL Patients Ag... Read Post »
Clinical TrialsJohnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Johnson & Johnson Strengthens IMAAVY FDA Filing With Positive ENERGY Re... Read Post »
Clinical TrialsSanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Sanofi Halts Phase 3 MOBILIZE Trial of Riliprubart in Refractory CIDP Read Post »
Clinical TrialsFDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA FDA Aligns on Phase 3 Design for Alterity’s ATH434 in MSA Read Post »
Clinical TrialsTango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Tango Sets Phase 3 Course for Vopimetostat-Daraxonrasib in MTAP-Deleted PDA... Read Post »
Clinical Trials82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study 82% of Patients Respond to BRIUMVI in Early Myasthenia Gravis Study Read Post »
Clinical TrialsGilead and Merck’s Once-Weekly HIV Pill Meets Phase 3 Goals Gilead and Merck’s Once-Weekly HIV Pill Meets Phase 3 Goals Read Post »
Clinical TrialsLilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral Semaglutide Lilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral Semaglutide Read Post »
Clinical TrialsElecoglipron Lowers HbA1c by 1.9% and Drives Weight Loss in Phase 2b Studie... Elecoglipron Lowers HbA1c by 1.9% and Drives Weight Loss in Phase 2b Studie... Read Post »
Clinical TrialsSurvodutide Delivers Up to 16.6% Weight Loss and Reduces Liver Fat in Phase... Survodutide Delivers Up to 16.6% Weight Loss and Reduces Liver Fat in Phase... Read Post »
Clinical TrialsCullinan Therapeutics Delivers CLN-978 Remission in Lupus and RA Cullinan Therapeutics Delivers CLN-978 Remission in Lupus and RA Read Post »
Clinical TrialsCagriSema Delivers Superior HbA1c and Weight Reduction Across Phase 3 REIMA... CagriSema Delivers Superior HbA1c and Weight Reduction Across Phase 3 REIMA... Read Post »
Clinical TrialsMazdutide Extends Lead Over Semaglutide in Detailed DREAMS-3 Results Mazdutide Extends Lead Over Semaglutide in Detailed DREAMS-3 Results Read Post »
Clinical TrialsSemaglutide Cuts Sleep Apnea Risk and Improves Cardiometabolic Health in Ne... Semaglutide Cuts Sleep Apnea Risk and Improves Cardiometabolic Health in Ne... Read Post »
Clinical TrialsRepatha Cuts Cardiovascular Events by 29% in High-Risk Diabetes Subgroup Repatha Cuts Cardiovascular Events by 29% in High-Risk Diabetes Subgroup Read Post »
Clinical TrialsRetatrutide Delivers Up to 28.3% Weight Loss and Improves Obesity-Related C... Retatrutide Delivers Up to 28.3% Weight Loss and Improves Obesity-Related C... Read Post »
Clinical TrialsAmneal Reports Positive Interim Result for CREXONT® in PD Amneal Reports Positive Interim Result for CREXONT® in PD Read Post »
Clinical TrialsNovo Nordisk Reports Strong Real-World Outcomes With Semaglutide 2 mg Escal... Novo Nordisk Reports Strong Real-World Outcomes With Semaglutide 2 mg Escal... Read Post »
Clinical TrialsPfizer’s Berobenatide Delivers Up to 15.9% Weight Loss, Supports Broa... Pfizer’s Berobenatide Delivers Up to 15.9% Weight Loss, Supports Broa... Read Post »
Clinical TrialsAstraZeneca Reports Positive Phase III Results for Ultomiris in IgAN AstraZeneca Reports Positive Phase III Results for Ultomiris in IgAN Read Post »
Clinical TrialsMannKind Reports New Afrezza Findings Across Pediatric and Adult Diabetes P... MannKind Reports New Afrezza Findings Across Pediatric and Adult Diabetes P... Read Post »
Clinical Trials Disease & DrugsInnovent’s Mazdutide Cuts BMI by Up to 11% in Adolescents with Obesity, A... Innovent’s Mazdutide Cuts BMI by Up to 11% in Adolescents with Obesity, A... Read Post »
Clinical TrialsNovo Nordisk’s Zenagamtide Lowers HbA1c by Up to 1.7% and Delivers 14.6% ... Novo Nordisk’s Zenagamtide Lowers HbA1c by Up to 1.7% and Delivers 14.6% ... Read Post »
Clinical TrialsBayer Reports Broad CKD Benefits with Finerenone in INFINITY Analysis Bayer Reports Broad CKD Benefits with Finerenone in INFINITY Analysis Read Post »
Clinical TrialsLundbeck’s PACAP Inhibitor Bocunebart Meets Endpoint in Migraine Lundbeck’s PACAP Inhibitor Bocunebart Meets Endpoint in Migraine Read Post »
Clinical TrialsBayer’s Finerenone Delivers Positive Phase III Results in Non-Diabeti... Bayer’s Finerenone Delivers Positive Phase III Results in Non-Diabeti... Read Post »
Clinical TrialsCosentyx Improves Long-Term Disease Control in Polymyalgia Rheumatica Cosentyx Improves Long-Term Disease Control in Polymyalgia Rheumatica Read Post »
Clinical TrialsAutobahn Posts Positive Data for Elunetirom in Bipolar Depression Autobahn Posts Positive Data for Elunetirom in Bipolar Depression Read Post »
Clinical TrialsInnovent Files China NDA for Arcotatug Tavatecan in Advanced Gastric Cancer Innovent Files China NDA for Arcotatug Tavatecan in Advanced Gastric Cancer Read Post »
Clinical TrialsNovartis Reports Positive Final Phase III Results for Vanrafia in IgA Nephr... Novartis Reports Positive Final Phase III Results for Vanrafia in IgA Nephr... Read Post »
Clinical TrialsImmutep Reports Positive Phase I Results for IMP761 in Autoimmune Disease Immutep Reports Positive Phase I Results for IMP761 in Autoimmune Disease Read Post »
Clinical TrialsJohnson & Johnson Reports Positive Phase 2 Lupus Data for Nipocalimab Johnson & Johnson Reports Positive Phase 2 Lupus Data for Nipocalimab Read Post »
Clinical Trialsargenx Shows Durable Efgartigimod Benefits in Myositis and Sjögren’s Dis... argenx Shows Durable Efgartigimod Benefits in Myositis and Sjögren’s Dis... Read Post »
Clinical TrialsTenaya’s TN-201 Shows Durable Benefits in MYBPC3-Associated HCM Tenaya’s TN-201 Shows Durable Benefits in MYBPC3-Associated HCM Read Post »
Clinical TrialsUCB Shows Long-Term Benefits of BIMZELX in PsA and axSpA UCB Shows Long-Term Benefits of BIMZELX in PsA and axSpA Read Post »
Clinical TrialsTakeda, Innovent Advance IBI363 With Strong Survival Data in Resistant NSCL... Takeda, Innovent Advance IBI363 With Strong Survival Data in Resistant NSCL... Read Post »
Clinical TrialsCelcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast... Celcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast... Read Post »
Clinical TrialsAbivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Abivax’s Obefazimod Meets All Phase 3 Endpoints in Ulcerative Colitis Read Post »
Clinical TrialsIDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... IDEAYA Scores Registrational Win for Darovasertib in Metastatic Uveal Melan... Read Post »
Clinical TrialsAstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 AstraZeneca’s Camizestrant Extends Progression-Free Survival in SERENA-6 Read Post »
Clinical TrialsIza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Iza-bren Extends Survival in Phase 3 Trials Across Triple-Negative Breast a... Read Post »
Clinical TrialsEntrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Entrada Advances ENTR-601-45 to Higher Dose Cohort in DMD Read Post »
Clinical TrialsIdorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Idorsia Reports Positive High-Dose Phase 1 Data for C. difficile Vaccine Read Post »
Clinical TrialsPersonalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Personalized mRNA Vaccine Plus KEYTRUDA Maintains Strong Melanoma Outcomes Read Post »
Clinical TrialsIdorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Idorsia Unveils New Phase 3 Evidence for Aprocitentan’s Renal Benefits Read Post »
Clinical TrialsNovartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Novartis Reports Strong Three-Year Scemblix Results in Newly Diagnosed CML Read Post »
